Search research articles
Contact Us
Filters
Showing results (341-350 of 369) with videos related to
Page
of 37
Sort By:
The Lancet. HIV
|
January 9, 2017
Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial
Jemma O'Connor, Michael J Vjecha, Andrew N Phillips, et al.
BMC Infectious Diseases
|
June 30, 2012
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
Alexandra Calmy, Eric Balestre, Fabrice Bonnet, et al.
The Journal of Infectious Diseases
|
October 8, 2025
Tuberculosis Disease Prevalence Among People Who Smoke Illicit Drugs: A Respondent- Driven Sampling Study in the Western Cape, South Africa
Samantha Malatesta, Tara Carney, Nandi Niemand Wolhuter, et al.
The Journal of Antimicrobial Chemotherapy
|
November 27, 2013
An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes
Andrew D Revell, Dechao Wang, Robin Wood, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
Peter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
June 7, 2023
Clinical utility of WHO-recommended screening tools and development and validation of novel clinical prediction models for pulmonary tuberculosis screening among outpatients living with HIV: an individual participant data meta-analysis
Ashar Dhana, Rishi K Gupta, Yohhei Hamada, et al.
The New England Journal of Medicine
|
July 21, 2015
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
, Jens D Lundgren, Abdel G Babiker, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 7, 2007
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
Bernard Barlaam, Peter Ballard, Robert H Bradbury, et al.
Tropical Medicine & International Health : TM & IH
|
July 4, 2024
Correcting mortality estimates among children and youth on antiretroviral therapy in southern Africa: A comparative analysis between a multi-country tracing study and linkage to a health information exchange
Patience Nyakato, Michael Schomaker, Andrew Boulle, et al.
The Lancet. Global Health
|
January 27, 2019
Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study
Krishna P Reddy, Ankur Gupta-Wright, Katherine L Fielding, et al.
Page
of 37
Search research articles
Search
Showing results (341-350 of 369) with videos related to
Sort By:
Page
of 37
The Lancet. HIV
|
January 9, 2017
Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial
Jemma O'Connor, Michael J Vjecha, Andrew N Phillips, et al.
BMC Infectious Diseases
|
June 30, 2012
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
Alexandra Calmy, Eric Balestre, Fabrice Bonnet, et al.
The Journal of Infectious Diseases
|
October 8, 2025
Tuberculosis Disease Prevalence Among People Who Smoke Illicit Drugs: A Respondent- Driven Sampling Study in the Western Cape, South Africa
Samantha Malatesta, Tara Carney, Nandi Niemand Wolhuter, et al.
The Journal of Antimicrobial Chemotherapy
|
November 27, 2013
An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes
Andrew D Revell, Dechao Wang, Robin Wood, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
Peter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
June 7, 2023
Clinical utility of WHO-recommended screening tools and development and validation of novel clinical prediction models for pulmonary tuberculosis screening among outpatients living with HIV: an individual participant data meta-analysis
Ashar Dhana, Rishi K Gupta, Yohhei Hamada, et al.
The New England Journal of Medicine
|
July 21, 2015
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
, Jens D Lundgren, Abdel G Babiker, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 7, 2007
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
Bernard Barlaam, Peter Ballard, Robert H Bradbury, et al.
Tropical Medicine & International Health : TM & IH
|
July 4, 2024
Correcting mortality estimates among children and youth on antiretroviral therapy in southern Africa: A comparative analysis between a multi-country tracing study and linkage to a health information exchange
Patience Nyakato, Michael Schomaker, Andrew Boulle, et al.
The Lancet. Global Health
|
January 27, 2019
Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study
Krishna P Reddy, Ankur Gupta-Wright, Katherine L Fielding, et al.
Page
of 37